SCHEMBL24927780

SCHEMBL24927780

CCOC(=O)c1ccc2c(c1)C(=O)c1ccc(Cl)cc1CC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.59
MAPT P10636 3/20 0.48
SRD5A1 P18405 2/20 0.47
SRD5A2 P31213 2/20 0.47
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 2/20 0.45
TSHR P16473 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPK1 P28482 2/20 0.45
SLC6A15 Q9H2J7 4/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
HRH1 P35367 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23058960 0.86 MAPK14 (0.58) MAPK14SRD5A1SRD5A2
SCHEMBL1918550 0.82 MAPT (0.58) MAPK14MAPTSRD5A1SRD5A2ALDH1A1
SCHEMBL23059138 0.81 MAPK14 (0.47) MAPK14MAPTALDH1A1NPC1TSHR
SCHEMBL11684948 0.80 SRD5A1 (0.72) MAPK14SRD5A1SRD5A2NR1H4
SCHEMBL30583381 0.79 BRD4 (0.55) MAPK14MAPTSRD5A1SRD5A2ALDH1A1
SCHEMBL31337617 0.79 BRD4 (0.55) MAPK14MAPTSRD5A1SRD5A2ALDH1A1
SCHEMBL26124045 0.79 MAPK14 (0.63) MAPK14
SCHEMBL10443684 0.78 CA12 (0.57) MAPK14MAPTSRD5A1SRD5A2ALDH1A1
SCHEMBL5846673 0.77 MAPT (0.68) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4179934 0.76 SRD5A1 (0.55) MAPK14MAPTSRD5A1SRD5A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230017312-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS SYNOVO GMBH (DE) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017312-A1 CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS MAPK1, MAPK8, MAPK7 MAPK14 10/4885MAPT 880/4885SRD5A1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.